Patients who takes low-dose aspirin (less than 324 mg) daily for ischemic stroke that had developed 1 month or more before entry.
Conditions
Interventions
Subjects in PPI group are administered rabeprazole 10 mg once daily.
Subjects in H2RA group are administered famotidine 20 mg twice daily.
Sponsors
Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with ischemic stroke that had developed 1 month or more before, 1) who are taking low-dose aspirin (less than 324 mg) daily, 2) who has some upper gastrointestinal symptoms (Score 1 or more for Frequency Scale for the Symptoms of GERD), and 3) in whom neither ulcers nor bleeding are observed at the initial endoscopy.
Exclusion criteria
Exclusion criteria: 1) Subjects in whom ulcers (3 mm or more in diameter) at the initial endoscopy. 2) Subjects who has been taking PPI at entry. 3) Subjects who has taken some NSAIDs other than aspirin within 1 month. 4) Subjects with a history of allergy for aspirin, rabeprazole or famotitine. 5) Subjects with severe liver damage, renal dysfunction, or congestive heart failure. 6) Subjects with malignancy. 7) Others.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) Symptoms 2) Quality of life 3) Erosion 4) Gastrroduodenal ulcer 5) Gastrointestinal bleeding | — |
Countries
Japan
Contacts
Public ContactTakayuki Matsumoto, Shotaro Nakamura
Graduate School of Medical Sciences, Kyushu University Department of Medicine and Clinical Science
Outcome results
None listed